2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5551 Impact of leukocytosis, thrombocytopenia, and splenomegaly documented within one year of polycythemia vera diagnosis: A propensity-matched cohort study

Kanishka Uttam Chandani, M.B.B.S., Jatin Thukral, MD2, Akshaya Keerti, MD3, Muhammad Ali Khan, MBBS4, Sooraj Srirangadhamu Gopu, MD5, Rishi Desai6, Jay Vyasa7, Mohamed Ayaan Sait, MBBS8, Ali Hassan, MD9, Diana Zamora, MD10, Usman Ilyas11, Jeanne Palmer, MD12
1 Mayo Clinic, Phoenix, Arizona, United States
2 New York Medical College/Landmark Medical Center, Woonsocket, Rhode Island, United States
3 Appalachian Regional Healthcare, Whitesburg, Kentucky, United States
4 Mayo Clinic, Phoenix, Arizona, United States
5 New York Medical College/Landmark Medical Center, Woonsocket, Rhode Island, United States
6 Georgetown University School of Medicine, Washington, D.C., United States
7 Saint Michael’s Medical Center, Newark, United States
8 PD Hinduja Hospital, Mumbai, India
9 Mayo Clinic, Phoenix, Arizona, United States
10 Mayo Clinic, Phoenix, Arizona, United States
11 Mayo Clinic, Phoenix, Arizona, United States
12 Mayo Clinic, Phoenix, Arizona, United States

BACKGROUND: Risk stratification in polycythemia vera (PV) has traditionally been anchored to age and prior thrombosis and has more recently expanded to also include leukocytosis (≥15 × 10?/L) and adverse mutations (SRSF2) per the Mutation-Enhanced International Prognostic Score (MIPSS-PV). We hypothesized that leukocytosis, thrombocytopenia, and splenomegaly, which are recognized as adverse features in myeloproliferative neoplasms (MPNs), might have prognostic implications for the disease trajectory if present or documented within 1 year of PV diagnosis. We quantified their prognostic impact as proof of concept for an automated electronic health record (EHR) tool that could be developed in the future to flag high-risk PV at first contact.

METHODS: We conducted a retrospective cohort study on the TriNetX Research network (118 healthcare organizations). Patients with PV (ICD-10 D45) were classified by the presence of 3 features recorded within 1 year of first PV diagnosis: leukocytosis (WBC >=15 x10^9/L), thrombocytopenia (platelets <=150 x10^9/L), and splenomegaly (R16.1). Each of these sub-cohorts was individually compared to PV patients without that feature. Cohorts were matched 1:1 by propensity score on demographics, cardiovascular and renal comorbidity, and medications (cytoreductive agents, aspirin, anticoagulants, statins, metformin). The outcomes studied were arterial, venous, and unusual-site thrombosis, GI bleed, intracranial hemorrhage, epistaxis, myelofibrosis (MF), AML/MDS, and all-cause mortality, which were analyzed at windows from 1 through 5 years (Kaplan-Meier, log-rank, Cox), excluding patients with the outcome before the window. Statistical significance was set at a log-rank p-value of <0.05.

RESULTS: Leukocytosis was noted in 12,309 of 70,930 (17.4%), thrombocytopenia in 13,162 of 86,509 (15.2%), and splenomegaly in 2,220 of 81,684 (2.7%) patients within 1 year of first PV diagnosis. We analyzed 4,380, 3,756, and 729 matched pairs in the leukocytosis, thrombocytopenia, and splenomegaly sub-cohorts. The median age was 66, 64, and 64 years across the leukocytosis, thrombocytopenia, and splenomegaly sub-cohorts. At 5 years, mortality was 23.3% vs 8.3% with leukocytosis (HR 3.23, 95% CI 2.86-3.64, p<0.001) and 24.1% vs 10.2% with thrombocytopenia (HR 2.64, 2.35-2.98, p<0.001). Leukocytosis was associated with increased MF (HR 3.72, 2.84-4.86, p<0.001), AML/MDS (HR 6.29, 3.69-10.73, p<0.001), arterial (HR 1.77, 1.50-2.09, p<0.001), venous (HR 2.14, 1.75-2.63, p<0.001), and unusual-site thrombosis (HR 3.35, 2.01-5.57, p<0.001). It was also associated with increased bleeding (GI HR 2.43, 1.94-3.05, p<0.001; intracranial HR 2.41, 1.68-3.46, p<0.001). Thrombocytopenia was associated with an increased risk of transformation to AML/MDS (HR 5.20, 3.03-8.92, p<0.001), and MF (HR 1.68, 1.24-2.26, p=0.001) with more modest vascular effects (arterial HR 1.51, 1.28-1.78, p<0.001; venous HR 1.70, 1.39-2.08, p<0.001). Splenomegaly was associated with the highest progression risk (MF HR 6.23, 3.69-10.51, p<0.001; AML/MDS HR 4.95, 2.64-9.29, p<0.001) and increased bleeding (GI HR 2.72, 1.67-4.45, p<0.001; epistaxis HR 2.90, 1.44-5.82, p=0.002) and mortality (HR 1.66, 1.27-2.16, p<0.001) without a statistically increased risk of arterial thrombosis (HR 1.01, 0.68-1.49, p=0.97). Excess hazard was front-loaded: mortality HR with leukocytosis fell from 4.07 (3.41-4.87, p<0.001) at 1 year to 3.43 (3.00-3.92, p<0.001) at 3 years and 3.23 (2.86-3.64, p<0.001) at 5 years, arterial thrombosis HR from 2.47 (1.93-3.16, p<0.001) to 1.77 (1.50-2.09, p<0.001), and mortality HR with thrombocytopenia from 3.05 (2.65-3.50, p<0.001) at 3 to 2.64 (2.35-2.98, p<0.001) at 5 years.

CONCLUSIONS: In this propensity-matched analysis, leukocytosis, thrombocytopenia, and splenomegaly documented within 1 year of PV diagnosis were each associated with higher 5-year mortality and with fibrotic and leukemic progression, with the excess hazard most pronounced in the first 1-3 years. Additionally, leukocytosis and thrombocytopenia were associated with higher thrombotic events. These findings are hypothesis-generating and highlight the need for prospective studies incorporating marrow and molecular correlates to determine whether these routinely available features add independent prognostic information to current risk models and whether they can inform management in PV.

Kanishka Uttam Chandani, M.B.B.S.: No relevant conflicts of interest to declare.